Inspire Medical Systems (NYSE:INSP) Shares Gap Down on Analyst Downgrade

Inspire Medical Systems, Inc. (NYSE:INSP)’s stock price gapped down prior to trading on Friday after Bank of America downgraded the stock from a neutral rating to an underperform rating. The stock had previously closed at $44.74, but opened at $42.89. Bank of America now has a $39.00 price target on the stock. Inspire Medical Systems shares last traded at $43.1350, with a volume of 226,925 shares traded.

Several other analysts have also weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. Robert W. Baird lowered their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. UBS Group set a $67.00 target price on shares of Inspire Medical Systems in a research note on Friday, February 13th. Truist Financial lowered their target price on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Finally, Evercore set a $55.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, May 5th. Four research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus price target of $81.84.

Institutional Trading of Inspire Medical Systems

Several institutional investors and hedge funds have recently bought and sold shares of INSP. CWM LLC raised its holdings in Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Inspire Medical Systems by 1,115.4% in the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares during the last quarter. Havemeyer Place LP acquired a new position in Inspire Medical Systems in the fourth quarter worth approximately $39,000. V Square Quantitative Management LLC acquired a new position in Inspire Medical Systems in the fourth quarter worth approximately $40,000. Finally, Smartleaf Asset Management LLC increased its holdings in Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Price Performance

The business has a fifty day moving average of $51.93 and a 200 day moving average of $76.52. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 9.56, a P/E/G ratio of 4.56 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. During the same quarter last year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts expect that Inspire Medical Systems, Inc. will post 0.91 EPS for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.